ELISA/assay

Rat isocitrate dehydrogenase, ICD ELISA Kit

MBS704509

48-Strip-Wells

565 USD

ELISA Kit

Rat isocitrate dehydrogenase, ICD ELISA Kit

isocitrate dehydrogenase 1 (NADP+) , soluble

Rat isocitrate dehydrogenase; ICD ELISA Kit; IDCD; IDH; IDP; IDPC; PICD; NADP+-specific ICDH; NADP-dependent isocitrate dehydrogenase; cytosolic; NADP-dependent isocitrate dehydrogenase; peroxisomal; OTTHUMP00000206464; OTTHUMP00000206465; OTTHUMP0; isocitrate dehydrogenase 1 (NADP+); soluble

isocitrate dehydrogenase; Isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase [NADP] cytoplasmic; isocitrate dehydrogenase [NADP] cytoplasmic; IDH; IDP; NADP(+)-specific ICDH; oxalosuccinate decarboxylase; Isocitrate dehydrogenase 1, soluble; cytosolic NADP-isocitrate dehydrogenase; isocitrate dehydrogenase 1 (NADP+), soluble; Cytosolic NADP-isocitrate dehydrogenase; IDP; NADP(+)-specific ICDH; Oxalosuccinate decarboxylase

IDH1

Idh1; Idh1; IDH

IDHC_RAT

Rat

414

This assay has high sensitivity and excellent specificity for detection of rat ICD. No significant cross-reactivity or interference between rat ICD and analogues was observed.

Unopened test kits should be stored at 2 to 8 degree C upon receipt. Please refer to pdf manual for further storage instructions.

Samples: Serum, plasma, tissue homogenates. Assay Type: Sandwich. Detection Range: 0.625 mIU/ml -40 mIU/ml. Sensitivity: The minimum detectable dose of rat ICD is typically less than 0.156 mIU/ml. The sensitivity of this assay, or Lower Limit of Detection (LLD) was defined as the lowest protein concentration that could be differentiated from zero. It was determined the mean O.D value of 20 replicates of the zero standard added by their three standard deviations.

Intra-assay Precision: Intra-assay Precision (Precision within an assay): CV%<8%. Three samples of known concentration were tested twenty times on one plate to assess. Inter-assay: Inter-assay Precision (Precision between assays): CV%<10%. Three samples of known concentration were tested in twenty assays to assess.

Principle of the assay: This assay employs the quantitative sandwich enzyme immunoassay technique. Antibody specific for ICD has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any ICD present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for ICD is added to the wells. After washing, avidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of ICD bound in the initial step. The color development is stopped and the intensity of the color is measured.

13928690

NP_113698.1

NM_031510.1

P41562

46,734 Da

2-Oxocarboxylic Acid Metabolism Pathway (716019); 2-Oxocarboxylic Acid Metabolism Pathway (717400); Abnormal Conversion Of 2-oxoglutarate To 2-hydroxyglutarate Pathway (1010547); Biosynthesis Of Amino Acids Pathway (791250); Biosynthesis Of Amino Acids Pathway (795174); Carbon Metabolism Pathway (816129); Carbon Metabolism Pathway (817567); Citrate Cycle (TCA Cycle) Pathway (83320); Citrate Cycle (TCA Cycle) Pathway (288); Citrate Cycle (TCA Cycle, Krebs Cycle) Pathway (855837)

catalyzes oxidative decarboxylation of citrate; cytosolic NADP+-dependent isozyme [RGD, Feb 2006]

IDH1: an oxidoreductase that catalyzes the third step of the TCA cycle: the oxidative decarboxylation of isocitrate, consuming NADP(+), and producing alpha-ketoglutarate (alpha-KG) and CO2. Alpha-KG is an activator the dioxygenases that hydroxylate the transcription factor HIF and lead to its degradation by VHL. Since HIF turns on oncogenic pathways, IDH1 has apparent tumor suppressor activity. Homo-dimerization is required for activity. Each subunit binds 1 magnesium or manganese ion. IDH1 is located in the cytosol and peroxisomes. Somatic mutations affecting arginine 132 (R132) are found in 80% of grade II?III gliomas and secondary glioblastomas in humans, and cause disease in a tissue-specific fashion. Only a single copy of the gene has been found to be mutated in tumours. Mutations of R132 to H, C, S, G, V, or L have been reported to be neomorphic, abolishing the conversion of isocitrate to alpha-KG. Instead, alpha-KG is converted to R(-)-2-hydroxyglutarate (2HG). Elevated levels of 2HG correlate with an elevated risk of malignant brain tumors. Neomorphic mutations in IDH1 and IDH2 convert alpha-KG to 2-hydroxyglutarate (2-HG) occur in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML). Protein type: EC 1.1.1.42; Carbohydrate Metabolism - citrate (TCA) cycle; Other Amino Acids Metabolism - glutathione; Oxidoreductase. Cellular Component: mitochondrion; cytoplasm; peroxisome; cytosol. Molecular Function: protein homodimerization activity; magnesium ion binding; isocitrate dehydrogenase (NADP+) activity; NADP binding; NAD binding; receptor binding. Biological Process: glyoxylate cycle; isocitrate metabolic process; glutathione metabolic process; tricarboxylic acid cycle; response to steroid hormone stimulus; response to oxidative stress; response to organic cyclic substance; female gonad development; 2-oxoglutarate metabolic process

48-Strip-Wells

565 USD

96-Strip-Wells

810

5x96-Strip-Wells

2750

10x96-Strip-Wells

5150